Frankly Speaking About Family Medicine

Available Episodes

5 of 455

Don’t Wait to Medicate—Evidence for Early Intervention in Hypertension - Frankly Speaking Ep 454
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-454 Overview: Treating hypertension within the first month can significantly improve long-term blood pressure control. This episode reviews new evidence and practical strategies to help you initiate timely therapy, optimize follow-up, and improve outcomes for patients with newly diagnosed, uncontrolled hypertension. Gain actionable insights to close a critical care gap. Episode resource links: Barrett, R. B., Riesser, B., Martin, B., Sachdev, N., Rakotz, M. K., Sutherland, S. E., & Egan, B. M. (2025). Treatment in the First Month After Hypertension Diagnosis Improves Blood Pressure Control. Hypertension (Dallas, Tex. : 1979), 82(6), 1129–1136. https://doi.org/10.1161/HYPERTENSIONAHA.124.23508 For your patients: 10 Ways to Control High Blood Pressure Without Medication For your patients: Natural Ways to Lower Blood Pressure Guest: Jill M. Terrien PhD, ANP-BC Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at [email protected]
--------
14:15
--------
14:15
Don’t Forget the Shingles Vaccine - Frankly Speaking Ep 453
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-453 Overview: Many patients are still hesitant about the shingles vaccine, but the benefits go far beyond preventing a painful rash. Hear how varicella zoster vaccination can also reduce the risks of postherpetic neuralgia, dementia, and cardiovascular events, giving you powerful tools to guide more informed patient decisions. Episode resource links: Dementia: Neurol Sci. 2024 Jan;45(1):27-36. doi: 10.1007/s10072-023-07038-7 CV: J Infect Dis. 2025 Feb 28:jiaf105. doi: 10.1093/infdis/jiaf105 Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at [email protected]
--------
12:26
--------
12:26
Autism and Acetaminophen—Separating Fact from Misinformation - Frankly Speaking Ep 452
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-452 Overview: The healthcare landscape is evolving rapidly, and clinicians are navigating conflicting guidance on established, evidence-based recommendations. Recent news suggest acetaminophen use during pregnancy causes autism spectrum disorder (ASD), which is not the consensus of medical experts based on available data. When guidance from various sources conflicts with established research, clinicians face challenges in providing evidence-based care. Join us to review the current evidence on acetaminophen and ASD risk. Episode resource links: Ahlqvist VH, Sjöqvist H, Dalman C, et al. Acetaminophen Use During Pregnancy and Children’s Risk of Autism, ADHD, and Intellectual Disability. JAMA. 2024;331(14):1205–1214. doi:10.1001/jama.2024.3172 Damkier, P., Gram, E. B., Ceulemans, M., Panchaud, A., Cleary, B., Chambers, C., Weber-Schoendorfer, C., Kennedy, D., Hodson, K., Grant, K. S., Diav-Citrin, O., Običan, S. G., Shechtman, S., & Alwan, S. (2025). Acetaminophen in Pregnancy and Attention-Deficit and Hyperactivity Disorder and Autism Spectrum Disorder. Obstetrics and gynecology, 145(2), 168–176. https://doi.org/10.1097/AOG.0000000000005802 Ji Y, Azuine RE, Zhang Y, et al. Association of Cord Plasma Biomarkers of In Utero Acetaminophen Exposure With Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood. JAMA Psychiatry. 2020;77(2):180–189. doi:10.1001/jamapsychiatry.2019.3259 Hirota T, King BH. Autism Spectrum Disorder: A Review. JAMA. 2023;329(2):157–168. doi:10.1001/jama.2022.23661 Liu, X., Zou, M., Sun, C., Wu, L., & Chen, W. X. (2022). Prenatal Folic Acid Supplements and Offspring's Autism Spectrum Disorder: A Meta-analysis and Meta-regression. Journal of autism and developmental disorders, 52(2), 522–539. https://doi.org/10.1007/s10803-021-04951-8 DSM-5-TR: Neurocognitive Disorders Supplement; October 2022. https://psychiatryonline.org/pb-assets/dsm/update/DSM-5-TR_Neurocognitive-Disorders-Supplement_2022_APA_Publishing.pdf https://www.npr.org/sections/shots-health-news/2025/09/06/nx-s1-5532143/hhs-responds-to-report-about-autism-and-acetaminophen Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at [email protected]
--------
16:59
--------
16:59
A Side-by-Side Look at GLP-1 RAs for Weight Loss - Frankly Speaking Ep 451
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-451 Overview: The obesity epidemic has fueled a demand for weight loss medications. Trials have directly compared medications—specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—with a recent study doing just that. Tune in as we explore the evidence comparing semaglutide and tirzepatide for weight loss outcomes up to 1 year. Episode resource links: Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064. Moiz A, Filion KB, Toutounchi H, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025;178(2):199-217. Wen J, Syed B, Nadora D, et al. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. Endocrinol Diabetes Metab. 2025;8(3):e70045. Guest: Alan M. Ehrlich, MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at [email protected]
--------
12:19
--------
12:19
DASHing Away Colon Cancer - Frankly Speaking Ep 449
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-449 Overview: In this episode, we discuss new evidence linking high compliance with the Dietary Approaches to Stop Hypertension (DASH) diet to lower risks of colorectal cancer, reinforcing the DASH diet’s well-established role in managing hypertension while also highlighting its potential to reduce cancer risk. Gain practical insights into translating these findings into actionable nutrition guidance to support your patients’ overall health. Episode resource links: Explain the risk factors for development of colorectal cancers Review the Dietary Approaches to Stop Hypertension (DASH) and discuss the proposed mechanisms for colorectal cancer reduction by following this approach Apply evidence from a meta-analysis to support dietary counseling strategies aimed at cancer prevention in clinical settings Guest: Jillian Joseph, MPAS, PA-C Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at [email protected]
--------
12:55
--------
12:55